Urology

JAMA

Volumn 281, Issue 6, 1999, Pages 495-496

  Litwin, Mark S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; SILDENAFIL;

BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CASTRATION; CIRCUMCISION; CLINICAL TRIAL; ERECTILE DYSFUNCTION; HUMAN; MALE TYPE ALOPECIA; ORAL DRUG ADMINISTRATION; PENIS DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PROSTATECTOMY; SHORT SURVEY;

EID: 0033540725     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.281.6.495     Document Type: Short Survey

References (13)

1. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro U. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, non-cholinergic neurotransmission. N Engl J Med. 1992; 326:90-94.
2. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA, for the Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction [published correction appears in N Engl J Med. 1998;339:59]. N Engl J Med. 1998;338:1397-1404.
3. Lepor H, Williford WO, Barry MJ, et al, for the Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med. 1996;335:533-539.
4. McConnell JD, Bruskewitz R, Walsh P, et al, for the Finasteride Long-Term Efficacy and Safety Study Group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 1998;338:557-563.
5. Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA. 1998;280:1604-1609.
6. Wasson JH. Finasteride to prevent morbidity from benign prostatic hyperplasia. N Engl J Med. 1998; 338:612-613.
7. Jacobsen SJ, Bergstralh EJ, Katusic SK, etal. Screening digital rectal examination and prostate cancer mortality: a population-based case-control study. Urology. 1998;52:173-179.
8. Surveillance, Epidemiology, and End Results (SEER) Program. Age-adjusted US cancer death rates. J Natl Cancer Inst. 1997;89:12.
9. Mettlin CJ, Murphy GP. Why is the prostate cancer death rate declining in the United States? [published correction appears in Cancer. 1998;82:1802]. Cancer. 1998;82:249-251.
10. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-974.
11. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998;280:975-980.
12. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998; 339:1036-1042.
13. Lander J, Brady-Fryer B, Metcalfe JB, Nazarali S, Muttitt S.Comparison of ring block, dorsal penile nerve block, and topical anesthesia for neonatal circumcision: a randomized controlled trial. JAMA 1997;278: 2157-2162.